STATUTORY RULES OF NORTHERN IRELAND

2018 No. 3

DANGEROUS DRUGS

The Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2018

Made - - - -	*10th January 2018*
Coming into operation	*31st January 2018*

The Department of Health(**1**) makes the following Order in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971(**2**), as adapted by section 7(9) of that Act and now vested in it(**3**) and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act.

Citation, commencement and extent

1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2018 and come into operation on 31st January 2018.

(2) The Interpretation Act (Northern Ireland) 1954(**4**) shall apply to this Order as it applies to an Act of the Assembly.

Amendment of the Misuse of Drugs (Designation) Order (Northern Ireland) 2001

2.—(1) The Misuse of Drugs (Designation) Order (Northern Ireland) 2001(**5**) is amended as follows.

(2) In paragraph 1(a) of Part 1 of the Schedule—

(a) Before "Bufotenine" insert—

"Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3a][1,4]benzodiazepine-1-yl)-N,N-dimethylmethanamine)

N-Benzyl-ethylphenidate

(**1**) The Department of Health, Social Services and Public Safety was renamed the Department of Health by section 1(5) of the Departments Act (Northern Ireland) 2016 (c. 5) (N.I.)
(**2**) 1971 c.38, as amended by section 151 of, and Schedule 17 to, the Police Reform and Social Responsibility Act 2011 (c. 13)
(**3**) S.R.&O. (N.I.) 1973 No. 504, Article 5(a) and S.I. 1999/283 (N.I.), Article 3(6)
(**4**) 1954 c.33 (N.I.)
(**5**) S.R. 2001 No. 431, relevant amending Orders are S.R. 2015 Nos. 228 and 54, S.R. 2014 Nos. 262, 159 and 20, S.R. 2013 No. 77, S.R. 2012 No. 212, S.R. 2011 No. 154, S.R. 2010 No. 246 and 149, S.R. 2009 no. 389 and S.R. 2005 No. 359

Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)";

(b) after "Cathinone" insert—

"4'-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)";

(c) after "Concentrate of poppy-straw" insert—

"Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

3,4-Dichloroethylphenidate

3,4-Dichloroethylphenidate (3,4-DCMP)

Dichlazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1.3-dihydro-2H-1,4-benzodiazepin-2-one)

Ethylnaphthidate

Ethylphenidate";

(d) after "Eticyclidine" insert—

"Etizolam";

(e) after "Etryptamine" insert—

"Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

4-Fluoroethylphenidate

4-Fluorometylphenidate

Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)";

(f) after "Gamma-butyrolactone" insert—

"3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

Isopropylphenidate (IPP or IPPD)";

(g) after "Lysergide and other N-alkyl derivatives of lysergamide" insert—

"Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)";

(h) after "Methcathinone" insert—

"4-Methylmethylphenidate

Methylmorphenate

Methylnaphthidate (HDMP-28)*N*-methyl-1-(thiophen-2-yl)propan-2-amine(methiopropamine or MPA)

Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

Propylphenidate";

(i) after "Psilocin" insert—

"Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)";

(j) after "3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)" insert—

"3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-menthylbenzamide (U-47,700)".

(3) For paragraph 1(pa)-(v) of Part 1 of the Schedule substitute—

"(q) Any compound structurally derived from 3-benzolindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl) methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

(r) Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl) methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantly ring to any extent;

(s) Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl (*N*-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent;

(sa) any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indomethacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraphs (h) to (s) above) structurally related to 1-penyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—

(i) replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4-b]pyridine;

(ii) replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmenthyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl,2-(4-morpholinyl)ethyl or(tetrahydropyran-4-yl)methyl;

(iii) replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methane group;

(iv) replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantly, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphythyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-